Biomerieux, Inc.

Centre National De La Recherche Scientifique

Université Paul Sabatier (toulouse Iii)

Biomerieux Sa

Universite Paul Sabatier

Chanel Parfums Beaute

Pierre Fabre Dermo-cosmetique

Guy Serre

Mireille Sebbag

Gaelle Saintigny

Nathalie Jonca

Eve Toulza

Marina Weber Vivat

Christian Vincent

Michel C Jolivet

Michel Simon

Colette Jolivet-Reynaud

Stéphane Poigny

Sylvie Daunes-Marion

Pascal T Dalbon

Hélène Duplan

Michel Arnaud

Odile Letourneur

Elisabeth Girbal-Neuhauser

Gerard Somme

Gaëlle Saintigny

Maria Léonor Nogueira

Brigitte Incaurgarat

Maria Leonor Nogueira

Cyril Clavel

Marie-Claire Mechin

Polypeptides belonging to the family of late proteins of the cornified envelope (LCE), fragments of the polypeptide, isolated nucleotide sequences encoding the polypeptides, and cosmetic and/or pharmaceutical compositions containing such polypeptides are described. The polypeptides have cosmetic and/or therapeutic use to reinforce the barrier function of the epidermis, prevent and/or treat the signs of skin dryness and prevent and/or treat disorders of the barrier function or the weakening of the epidermis.

Polypeptide expressed in the stratum corneum and use thereof

The present invention relates to the activation of peptidyl arginine deiminase (PADs) 1 and/or 3 in the epidermis by at least one active agent used alone or in combination, namely caffeine, acefylline and/or theobromine in a cosmetic and/or pharmaceutical composition. The present invention also relates to the use of the aforementioned active agents in cosmetics and/or therapeutics, alone or in combination, in order to improve the barrier functions of the epidermis, to prevent and/or treat symptoms related to dry skin or to improve and/or promote hydration of the keratinous layer. Finally, the invention relates to increasing the activity of PAD1 and/or PAD3 in the epidermis.

Peptidyl arginine deiminase 1 and/or 3 activator compounds in the epidermis and uses thereof

The invention relates to citrulline peptides with anti-inflammatory properties. The invention also relates to an in vitro model for activation of macrophages, induced by immune complexes between specified IgG of rheumatoid arthritis and their citrulline targets.

Peptides modulating the activity of macrophages, useable for the treatment of rheumatoid arthritis

The invention relates to novel citrulline peptides derived from fibrin &#x3b1; and &#x3b2; chains which are recognizable by specific citrulline antiprotein autoantibodies (AAPC) of a rheumatoid arthritis (PR) and to the use thereof for detecting the presence of said specific PR AAPC in a biological sample.

Citrulline peptides derived from fibrin and recognized by rheumatoid arthritis specific autoantibodies, and the use thereof

A novel polypeptide isolated from the cornified envelope, similar polypeptides and fragments of the polypeptide, isolated nucleotide sequences encoding the polypeptides, as well as a cosmetic and/or pharmaceutical composition containing such polypeptides are described. The polypeptides have cosmetic and/or therapeutic use to reinforce the barrier function of the epidermis, prevent and/or treat the signs of skin dryness and prevent and/or treat disorders of the barrier function or the weakening of the epidermis.

Polypeptide expressed in the stratum corneum and thereof

A method for detecting anti-filaggrin-autoantibodies specific to rheumatoid arthritis in a biological sample, by providing a filaggrin with no citrulline residues (FNC) having an arginine residue or a filaggrin peptide with no citrulline residues (PFNC) having an arginine residue. Also provided are a citrulline-containing filaggrin (FC) having the peptide sequence of the FNC where some arginine residues have been converted to citrulline residues or a citrulline-containing peptide (PFC) having the peptide sequence of the PFNC, where at least one arginine residue has been converted to a citrulline residue. The sample is contacted with the FNC or PFNC and the FC or PFC, and the resulting immune complexes are detected and quantified, with a value Xand X, respectively. Anti-filaggrin-autoantibodies specific to rheumatoid arthritis are determined to be present in the biological sample if the value of Xis greater than the value of X.

Method for detecting rheumatoid arthritis-specific autoantibodies

The invention concerns citrulline polypeptide derived from fibrin useful for diagnosing or treating rheumatoid arthritis.

Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis

The invention concerns an artificial antigen specifically identified by the anti-filaggrin autoantibodies present in the serum of patients suffering from rheumatoid polyarthritis, and consisting of one polypeptide comprising all or part of the sequence of one filaggrin unit or of a related molecule, in which an arginine radical has been substituted by a citrulline radical. The invention also concerns the use of this antigen for diagnosing rheumatoid polyarthritis.

Antigens derived from filaggrin and their use for diagnosing rheumatoid polyarthritis

The present invention relates to antigens extracted from mammalian malpighian epithelia, in particular rat esophageal epithelium or human epidermis, which are specifically recognized by the autoantibodies present in patients suffering form rheumatoid arthritis in respect of antigenic determinants in common with filaggrin and human profilaggrin, as well as to the antigenic proteins of which said antigens are composed and to the peptide fragments derived therefrom. The invention relates to the use of these antigens, proteins and peptide fragments, and that of filaggrin and human profilaggrin, for the preparation of antigenic compositions, and to their applications, in particular for the diagnosis of rheumatoid arthritis. The invention also relates to the preparation of antibodies directed towards these antigens, and to their applications.

Antigens recognized by antibodies to rheumatoid arthritis, their

Growing community of inventors

Toulouse, France

Guy Serre